Ann: FDA Technegas Approval Webinar, page-41

I'm not sure how actively the CEO and company push for broad institutional share holdings. I believe (although not sure) that a large percentage of shares are held by entities closely aligned with the company which makes things very comfortable for management. They all seem happy to play a very long game with little concern for the near term share price and not great for anyone wanting to take profits from a spike after approval. Unfortunately with all the world turmoil money is likely to drain from shares and people get nervous so this could take time. I can handle that but would be so much happier with more obvious signs of promoting the recent success. I don't think anyone was expecting this kind of retrace. There was that announcement implying a valuation around $3 for an employee share scheme so the current situation is of zero value to them too.